Preclinical Development of mPGES-1 & 5-LOX selective inhibitors for Colon Cancer

mPGES-1的临床前开发

• 批准号: 8571067
• 金额: $ 81.95万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-21 至 2014-09-20
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8571067
• 关键词: American; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Cancer Etiology; Clinical Research; Colon Carcinoma; Colorectal Cancer; Contractor; Development; Diagnosis; Dose; Epithelial; Inflammation Mediators; Intestinal Neoplasms; Malignant Neoplasms; Maximum Tolerated Dose; Metabolism; Modeling; Mus; Rattus; Testing; cancer prevention; colorectal cancer prevention; inhibitor/antagonist; mouse model; pre-clinical; preclinical study; prostaglandin E synthase-1

Every year 150,000 Americans are diagnosed with colorectal cancer, the second leading cause of cancer-related mortaliy in the US. Over the past two decases, preclinical and clinical studies and extensive mechanistic studies support the importance of inflammatory mediators, particulary those derived for arachidonic acid metabolism, in the progression of many epithelial cancers, particularly in colorectal cancer.

每年有15万美国人被诊断患有结直肠癌，这是美国癌症相关死亡的第二大原因。在过去的二十年中，临床前和临床研究以及广泛的机制研究支持炎症介质的重要性，特别是那些衍生的花生四烯酸代谢，在许多上皮癌，特别是在结直肠癌的进展。